Glaukos (NYSE:GKOS) Announces Earnings Results, Misses Estimates By $0.02 EPS

Glaukos (NYSE:GKOS) posted its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02), Zacks reports. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. Glaukos updated its FY 2025 guidance to EPS.

Glaukos Trading Down 1.6 %

Shares of Glaukos stock opened at $157.97 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos has a one year low of $83.90 and a one year high of $163.71. The firm has a fifty day moving average of $153.00 and a two-hundred day moving average of $139.16.

Insiders Place Their Bets

In other Glaukos news, Director Gilbert H. Kliman sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the sale, the director now directly owns 32,336 shares of the company’s stock, valued at $4,859,454.08. This trade represents a 23.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Joseph E. Gilliam sold 3,328 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $15,310,024.65. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,744 shares of company stock worth $2,792,151. 6.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of analyst reports. Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a research note on Monday, December 2nd. BTIG Research upped their target price on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and upped their target price for the stock from $132.00 to $162.00 in a research note on Wednesday, December 11th. Wells Fargo & Company boosted their price target on shares of Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Finally, Truist Financial upped their target price on shares of Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $159.42.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.